Nobody actually wants more growth hormone. What people want is what they have been told it delivers: deeper sleep, faster recovery, more lean tissue, less fat, and a morning where the body feels as though it used the eight hours it was given.
Those are outcomes. Growth hormone concentration is a marker. The distance between the two is the single most useful concept in reading health claims, and it is where a great deal of marketing quietly lives.
A marker is something measurable that is believed to sit on the path to an outcome. It is attractive because it moves quickly, it can be measured in a blood sample, and a study using one can be small and short. An outcome is the thing a person actually cares about: how they sleep, how much they can lift, whether the injury healed, how long they live.
The peptides most commonly sold for growth hormone support, usually CJC-1295 paired with ipamorelin, are an unusually clean illustration. The human studies behind them are real, competently conducted, and published in a respected endocrinology journal. They measured markers. What happens when you follow the chain from those markers to the outcomes being advertised is the subject of this article. If you are already following supply, you can check current CJC-1295 and ipamorelin availability before reading on.
Key takeaways
- A surrogate marker is a stand-in for an outcome, and the substitution is often wrong.
- Published human studies show CJC-1295 raises growth hormone and IGF-1 substantially and for days.
- No published trial establishes that the marketed combination improves sleep, body composition, recovery or strength.
- FDA evaluated both compounds in late 2024 and the criteria weighed against both; for ipamorelin it found no safety data for the injected route proposed.
- A Phase 2 trial of one compound was stopped in 2006 after a participant died.
View the blend composition and specifications →
The Difference Between a Marker and an Outcome
Medicine has a long and instructive history of surrogate markers that turned out to point the wrong way.
The most cited example concerns heart rhythm. After a heart attack, some patients develop extra ventricular beats, and those extra beats are associated with a higher risk of sudden death. Drugs existed that suppressed them reliably. The marker improved, the logic was clean, and the drugs were widely used. When a trial finally measured the outcome rather than the marker, the patients receiving the drugs were dying more often, not less. Suppressing the marker had not addressed the thing the marker was a sign of.
Bone density tells a similar story in a smaller way. Certain treatments increase measured density while doing little or nothing for fracture risk, which is the outcome that matters. Density is a good marker precisely often enough to be dangerous.
The lesson is not that markers are useless. Markers are how research makes progress efficiently, and some are well validated, meaning that moving them has been repeatedly shown to move the outcome. HbA1c has earned that status for diabetes complications. LDL cholesterol has broadly earned it for cardiovascular events.
Validation is the key word, and it is earned empirically rather than argued from mechanism. Until a marker has been shown to track an outcome across multiple interventions, a change in it is a reason to run a proper trial, not a substitute for one.
IGF-1 has not been validated as a surrogate for sleep quality, muscle gain, fat loss or recovery from injury. That is not a technicality. It is the central issue.
How the Body Actually Releases Growth Hormone
Growth hormone is not secreted at a steady rate. The pituitary releases it in discrete pulses, most prominently during slow-wave sleep early in the night, with smaller pulses through the day. Between pulses, concentrations fall to very low levels.
Two hypothalamic signals govern this. Growth hormone-releasing hormone, GHRH, stimulates release. Somatostatin inhibits it. The interplay of the two produces the pulsatile pattern, and the troughs between pulses appear to matter as much as the peaks, because receptors resensitise during the quiet periods.
Most circulating growth hormone acts indirectly. It travels to the liver and other tissues and prompts production of insulin-like growth factor 1, IGF-1, which carries out much of the downstream effect on tissue. IGF-1 is far more stable in blood than growth hormone itself, which is why it is the value actually measured in a laboratory. Measuring growth hormone directly would mean catching a pulse, which requires repeated sampling over hours.
So IGF-1 is already a surrogate at the first step: a convenient stable proxy for a pulsatile hormone that is difficult to measure. That is perfectly reasonable as laboratory practice. It simply means a reported IGF-1 value is two steps removed from any outcome a person cares about.
What the Two Peptides Do to the Signal
CJC-1295 is a synthetic analogue of GHRH, engineered for a much longer duration of action than the natural hormone, which is cleared within minutes. Some versions include a modification, referred to as DAC, that binds the molecule to albumin in the blood and extends its life dramatically.
Ipamorelin works through a different receptor entirely. It mimics ghrelin, the hormone associated with hunger, at the growth hormone secretagogue receptor, which is a second and independent route to stimulating release.
The rationale for combining them is that two complementary signals should produce more release than either alone, in a pattern closer to natural physiology than injecting growth hormone itself. As reasoning goes, this is more sophisticated than most of what the peptide market offers.
It is worth noting what the combination is not. Neither compound is a component of any approved medicine. Neither has a monograph in the United States Pharmacopeia. The combination is a market convention rather than a formulation that has been through any development process.
What the Human Studies Actually Measured
Two studies published in the Journal of Clinical Endocrinology and Metabolism in 2006 are the backbone of the human evidence, and they are worth describing accurately because they are genuinely good studies.
The first, by Teichman and colleagues, comprised two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61. After single doses, mean growth hormone concentrations rose by two- to tenfold for six days or more, and mean IGF-1 rose by 1.5- to threefold for nine to eleven days. The estimated half-life was between about six and eight days. No serious adverse reactions were reported.
The second, by Ionescu and Frohman, addressed a specific worry. Continuous stimulation might flatten the pulsatile pattern, and since pulsatility appears physiologically important, that would be a meaningful drawback. Sampling blood every twenty minutes overnight in healthy men, they found the frequency and magnitude of growth hormone pulses were unaltered. Trough concentrations rose about sevenfold, mean growth hormone rose by 46 percent, and IGF-1 rose by 45 percent.
Read those results carefully and notice what every reported number is. Growth hormone concentration. IGF-1 concentration. Pulse frequency and amplitude. Half-life. Every single one is a measurement of the signal.
Not one is a measurement of sleep quality, lean mass, fat mass, strength, recovery time or injury healing. The studies did not claim otherwise; they were pharmacology studies, and they answered their own question well. The claims attached to these compounds in the marketplace are simply about different things than the studies measured.
| What was measured | What is marketed | Studied in humans? |
|---|---|---|
| Growth hormone concentration | Deeper sleep | Not for this combination |
| IGF-1 concentration | Muscle gain | Not for this combination |
| Pulse frequency and amplitude | Fat loss | Not for this combination |
| Half-life and duration | Faster injury recovery | Not for this combination |
The gap in the right-hand column is the whole argument. It is not a claim that the compounds do nothing. It is a statement that the outcomes being sold have not been measured.
Limited monthly batches
CJC/Ipamorelin Blend 10mg
CJC-1295 + ipamorelin · 99%+ HPLC purity · Research-grade peptide
What Regulators Found on Effectiveness and Safety
Both compounds went before FDA’s Pharmacy Compounding Advisory Committee in late 2024, ipamorelin in October and CJC-1295 in December, and briefing documents were published for each.
For ipamorelin, the agency concluded that evidence of effectiveness for the proposed conditions was limited by any route, and that there were no data supporting effectiveness by the subcutaneous route the nomination proposed. It also stated plainly that there are no safety data for ipamorelin administered by that proposed route. It noted that professional society guidelines do not discuss it, and that preparations are increasingly marketed by medical spas and wellness clinics.
For CJC-1295, the agency found that the nominations included no articles discussing effectiveness in humans with growth hormone deficiency, and that the only human studies were in healthy adults. It stated there are no data on effectiveness for that condition. It also made a point that is easy to miss and quite important: patients with complete growth hormone deficiency will not respond to a secretagogue at all, because these compounds work by stimulating a pituitary that in such patients cannot respond.
Both evaluations concluded that a balancing of the criteria weighed against adding the substances to the compounding list. For CJC-1295 the stated reasons included unclear physicochemical characterisation arising from inconsistent naming, limited information about historical compounding use, safety concerns identified in nonclinical toxicity studies, and the absence of clinical safety and effectiveness data.
One further item from the CJC-1295 document deserves to be stated directly, because it does not appear in most discussion of these compounds. The developer withdrew the long-acting DAC version from clinical trials in 2006 following the death of a participant in a Phase 2 trial. The briefing document records this. A single death in a trial does not establish that a compound caused it, and the circumstances are not detailed in the document. But a development programme halted after a death is a materially different history from a compound that simply never attracted investment, and anyone weighing the risk deserves to know it happened.
The same document also notes that preparations identified as containing CJC-1295 have turned up in seizures by police and customs authorities, which says something about the supply chain that exists around it.
Why More Growth Hormone Is Not Automatically Better
The assumption underneath the entire category is that raising a hormone that declines with age restores something lost. That assumption is worth examining, because the growth hormone axis does not operate in isolation.
Growth hormone opposes insulin. Raising it tends to reduce insulin sensitivity and can raise blood glucose, which is why glucose monitoring forms part of the management of approved growth hormone therapy. Fluid retention is common, presenting as swelling, joint pain, or carpal tunnel symptoms when swelling compresses the nerve at the wrist. These are well documented with approved growth hormone products and are dose-related.
IGF-1 is also, as the name says, a growth factor. It promotes cell proliferation and inhibits programmed cell death. That is exactly what is wanted in a healing tendon and exactly what is not wanted in a cell population that has already begun behaving abnormally. This is why approved growth hormone therapies are contraindicated in active malignancy and why IGF-1 is monitored during treatment rather than maximised.
The age-related decline in growth hormone is itself not clearly a defect to be corrected. It is a consistent feature of normal ageing, and whether reversing it produces net benefit is an open question rather than an established one.
None of this makes the axis untouchable. Approved growth hormone medicines exist and are genuinely valuable for people with diagnosed deficiency. The structure around them is the point: a diagnosis established by proper testing, screening for contraindications, a defined dose, and monitoring of glucose, IGF-1 and symptoms. That structure exists because the risks are real and dose-dependent.
Measuring the Outcome You Actually Care About
The practical response to all of this is straightforward, and it applies well beyond peptides.
Decide what outcome matters before choosing anything to change it, then measure that outcome directly. If the goal is sleep, measure sleep: total time, time to fall asleep, awakenings, and how mornings feel, recorded consistently over weeks. If the goal is strength, measure strength, with the same lifts under the same conditions. If the goal is body composition, use a method with acceptable precision, DXA if available, and allow enough time for a real change to exceed the measurement error, which usually means three months rather than three weeks.
Measure a baseline before starting, because retrospective impressions are unreliable and motivated. Change one variable at a time, since starting a compound in the same month as a new training programme and better sleep hygiene makes attribution impossible. And decide in advance what result would count as failure, because an intervention with no stopping rule tends to continue indefinitely.
If symptoms genuinely suggest a hormone disorder, that is a diagnostic question with an established pathway: an endocrinologist, proper dynamic testing, and if a deficiency is confirmed, approved therapy with monitoring. Growth hormone deficiency is a real condition with effective treatments, and self-treating a suspected version of it with an unapproved compound forgoes both the diagnosis and the therapy that would follow.
The underlying scientific question, whether the body’s own recovery rhythm can be supported safely and usefully, is a good one. The honest answer today is that the marketed outcomes have not been demonstrated in rigorous human trials. Follow the signal if it interests you. Just do not mistake it for the finish line.
Check If the October Batch Is Still Available
99%+ HPLC purity · Third-party tested · Fast U.S. shipping
Due to manufacturing constraints, inventory may be limited.
Frequently asked questions
Does a higher IGF-1 result mean the compound is working?
It means the compound is doing something measurable to the growth hormone axis. Whether that translates into better sleep, more muscle or faster recovery is a separate question that the marker cannot answer. A marker rising confirms biological activity, not benefit.
Why can a surrogate marker point the wrong way?
Because it captures one step in a complex system while missing others. A drug can improve a marker through one mechanism while causing harm through another, and only an outcome measurement detects the net effect. This has happened repeatedly in medicine, most famously with drugs that suppressed abnormal heart rhythms while increasing deaths.
Are these compounds the same as prescription growth hormone?
No. Approved therapy supplies growth hormone directly. These compounds attempt to stimulate the pituitary to release more of its own, which means they cannot work at all in someone whose pituitary cannot respond. FDA made that point specifically about complete growth hormone deficiency.
What should someone with genuine symptoms do?
Seek a diagnosis rather than a product. Fatigue, poor recovery and changes in body composition have many causes, most of them commoner than growth hormone deficiency. If a deficiency is confirmed by proper testing, approved treatments exist with established dosing and monitoring.
How long should a fair self-test run?
Longer than most people allow. Body composition changes slowly enough that anything under about twelve weeks is mostly measurement noise. Strength can be assessed sooner but is confounded by training. Sleep needs several weeks of consistent recording to separate signal from ordinary variation, and a baseline recorded before starting is essential.
This is education, not medical advice. Laboratory results only carry meaning alongside your symptoms, history and examination. Talk to a qualified clinician about your own results before changing anything about your care or supplements.
